Logo image of BCYC

BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Fundamental Analysis

USA - NASDAQ:BCYC - US0887861088 - ADR

7.88 USD
+0.07 (+0.9%)
Last: 10/24/2025, 8:10:30 PM
7.88 USD
0 (0%)
After Hours: 10/24/2025, 8:10:30 PM
Fundamental Rating

3

Taking everything into account, BCYC scores 3 out of 10 in our fundamental rating. BCYC was compared to 534 industry peers in the Biotechnology industry. BCYC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BCYC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BCYC has reported negative net income.
In the past year BCYC has reported a negative cash flow from operations.
BCYC had negative earnings in each of the past 5 years.
In the past 5 years BCYC always reported negative operating cash flow.
BCYC Yearly Net Income VS EBIT VS OCF VS FCFBCYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of BCYC (-29.12%) is better than 67.60% of its industry peers.
BCYC has a Return On Equity of -36.23%. This is in the better half of the industry: BCYC outperforms 73.97% of its industry peers.
Industry RankSector Rank
ROA -29.12%
ROE -36.23%
ROIC N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
BCYC Yearly ROA, ROE, ROICBCYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

BCYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCYC Yearly Profit, Operating, Gross MarginsBCYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCYC has more shares outstanding
Compared to 5 years ago, BCYC has more shares outstanding
The debt/assets ratio for BCYC has been reduced compared to a year ago.
BCYC Yearly Shares OutstandingBCYC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BCYC Yearly Total Debt VS Total AssetsBCYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.56, we must say that BCYC is in the distress zone and has some risk of bankruptcy.
BCYC's Altman-Z score of 0.56 is fine compared to the rest of the industry. BCYC outperforms 60.11% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that BCYC is not too dependend on debt financing.
BCYC's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BCYC outperforms 49.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.56
ROIC/WACCN/A
WACC9.27%
BCYC Yearly LT Debt VS Equity VS FCFBCYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BCYC has a Current Ratio of 10.39. This indicates that BCYC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.39, BCYC belongs to the top of the industry, outperforming 82.58% of the companies in the same industry.
A Quick Ratio of 10.39 indicates that BCYC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.39, BCYC belongs to the best of the industry, outperforming 82.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.39
Quick Ratio 10.39
BCYC Yearly Current Assets VS Current LiabilitesBCYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

BCYC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.04%.
The Revenue for BCYC has decreased by -51.28% in the past year. This is quite bad
The Revenue has been growing by 20.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)6.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-48.05%
Revenue 1Y (TTM)-51.28%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%-68.81%

3.2 Future

BCYC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.46% yearly.
Based on estimates for the next years, BCYC will show a very strong growth in Revenue. The Revenue will grow by 55.48% on average per year.
EPS Next Y-44.75%
EPS Next 2Y-21.63%
EPS Next 3Y-9.99%
EPS Next 5Y-1.46%
Revenue Next Year-24.14%
Revenue Next 2Y-12.92%
Revenue Next 3Y9.91%
Revenue Next 5Y55.48%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCYC Yearly Revenue VS EstimatesBCYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BCYC Yearly EPS VS EstimatesBCYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCYC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCYC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCYC Price Earnings VS Forward Price EarningsBCYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCYC Per share dataBCYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

A cheap valuation may be justified as BCYC's earnings are expected to decrease with -9.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.63%
EPS Next 3Y-9.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCYC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (10/24/2025, 8:10:30 PM)

After market: 7.88 0 (0%)

7.88

+0.07 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners88.72%
Inst Owner Change-0.24%
Ins Owners1.37%
Ins Owner Change0.24%
Market Cap546.14M
Revenue(TTM)19.28M
Net Income(TTM)-242362000
Analysts82
Price Target24.91 (216.12%)
Short Float %3.15%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.94%
Min EPS beat(2)-17.46%
Max EPS beat(2)-2.43%
EPS beat(4)2
Avg EPS beat(4)-1.58%
Min EPS beat(4)-17.46%
Max EPS beat(4)7.19%
EPS beat(8)5
Avg EPS beat(8)9.8%
EPS beat(12)6
Avg EPS beat(12)4.44%
EPS beat(16)7
Avg EPS beat(16)1.24%
Revenue beat(2)1
Avg Revenue beat(2)-20.74%
Min Revenue beat(2)-67.15%
Max Revenue beat(2)25.67%
Revenue beat(4)1
Avg Revenue beat(4)-34.05%
Min Revenue beat(4)-67.15%
Max Revenue beat(4)25.67%
Revenue beat(8)3
Avg Revenue beat(8)5.44%
Revenue beat(12)5
Avg Revenue beat(12)12.16%
Revenue beat(16)6
Avg Revenue beat(16)7.05%
PT rev (1m)0%
PT rev (3m)-8.15%
EPS NQ rev (1m)0.6%
EPS NQ rev (3m)-7.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.33
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-4.36
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-3.01
OCFYN/A
SpS0.28
BVpS9.65
TBVpS9.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.12%
ROE -36.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.44%
Cap/Sales 9.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.39
Quick Ratio 10.39
Altman-Z 0.56
F-Score2
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)192.2%
Cap/Depr(5y)162.86%
Cap/Sales(3y)48.56%
Cap/Sales(5y)34.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-48.05%
EPS Next Y-44.75%
EPS Next 2Y-21.63%
EPS Next 3Y-9.99%
EPS Next 5Y-1.46%
Revenue 1Y (TTM)-51.28%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%-68.81%
Revenue Next Year-24.14%
Revenue Next 2Y-12.92%
Revenue Next 3Y9.91%
Revenue Next 5Y55.48%
EBIT growth 1Y-57.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.64%
EBIT Next 3Y-2.89%
EBIT Next 5YN/A
FCF growth 1Y-280.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-329.66%
OCF growth 3YN/A
OCF growth 5YN/A

BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ

What is the fundamental rating for BCYC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCYC.


What is the valuation status of BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?

ChartMill assigns a valuation rating of 0 / 10 to BICYCLE THERAPEUTICS PLC-ADR (BCYC). This can be considered as Overvalued.


What is the profitability of BCYC stock?

BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a profitability rating of 1 / 10.